Macro Highlights - The State Council issued an opinion to release the potential of sports consumption and promote high-quality development of the sports industry, proposing 6 key measures with 20 specific actions [1] - The measures include expanding the supply of sports products, stimulating consumer demand, strengthening sports enterprises, fostering growth points in the sports industry, enhancing support for industry elements, and improving service levels [1] - The National Standardization Administration plans to revise and formulate over 4,000 national standards focusing on key areas such as artificial intelligence and the Internet of Things to support the transformation and upgrading of the manufacturing industry [1] Company News - Jiahe Meikang announced that Hongyun Jiukang plans to reduce its stake in the company by no more than 1% [4] - Bolong Technology's supervisory board chairman intends to reduce his stake by no more than 0.75% [4] - Lianhuan Pharmaceutical received a drug registration certificate for Amlodipine Besylate Tablets [4] - Tianyu Co., Ltd. obtained a drug registration certificate for Candesartan Cilexetil Tablets [4] - Kebo Da plans to acquire 60% of Kebo Da Intelligent Technology for 345 million yuan [4] - Youyan Powder Materials reported that its newly developed heat dissipation copper powder cannot be used as a 3D printing material [4] - Southeast Network Frame won the bid for the joint development project of Wuyuan Street [4] - Lepu Medical completed the first dosing of the Phase II clinical trial for MWN105 injection [4] - Zhonghaidah clarified that its designated robot company is not UBTECH [4] - Information Development aims to expand cooperation opportunities with the Robotaxi industry chain [4] Additional Company News - Jingong Steel Structure's subsidiary won a land bid in Shanghai for 546 million yuan [5] - Fuyuan Pharmaceutical received a drug registration certificate for Amlodipine Benazepril Capsules [5] - Ningbo Construction's subsidiary won construction projects totaling 1.117 billion yuan [5]

Group 1 - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Norde Pharmaceutical Co., Ltd., has recently received the Drug Registration Certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [2]

Group 1 - The core point of the article is that Tianyu Co., Ltd. has received approval from the National Medical Products Administration for the drug registration certificate of Candesartan Cilexetil Tablets, which are indicated for primary hypertension [1] Group 2 - The approval was granted to Zhejiang Norde Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tianyu Co., Ltd. [1] - Candesartan Cilexetil Tablets are specifically used for the treatment of primary hypertension [1]

格隆汇9月4日丨天宇股份(300702.SZ)公布，公司全资子公司浙江诺得药业有限公司(简称"诺得药业")于 近日收到国家药品监督管理局核准签发的关于坎地沙坦酯片的《药品注册证书》。 坎地沙坦酯片适用于原发性高血压。根据国家药监局网站数据查询，截至公告日，该制剂除诺得药业 外，国内生产商另有天地恒一制药股份有限公司、广州白云山天心制药股份有限公司等11家企业。 ...

Group 1 - The company Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [1] - Candesartan Cilexetil Tablets are indicated for primary hypertension, with a total R&D investment of approximately 11.4476 million yuan by Node Pharmaceutical and its subsidiaries [1] - The projected sales revenue for Candesartan Cilexetil Tablets in domestic sample hospitals and urban retail pharmacies is approximately 294 million yuan in 2024 [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration, indicating the product's approval for the treatment of primary hypertension [1]. Company Summary - Tianyu Co., Ltd. has successfully obtained regulatory approval for Candesartan Cilexetil Tablets, which are indicated for primary hypertension [1]. - The approval enhances the product portfolio of Zhejiang Node Pharmaceutical Co., Ltd., potentially increasing its market presence in the hypertension treatment segment [1].

Group 1 - The company Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Norde Pharmaceutical Co., Ltd. has recently received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [1] - Candesartan Cilexetil Tablets are indicated for the treatment of primary hypertension [1]

Core Viewpoint - The report from Tianfeng Securities indicates that Baiyunshan's fundamentals remain stable while expanding its overseas market presence [1] Financial Performance - In the first half of 2025, Baiyunshan's southern medicine segment achieved revenue of 5.241 billion yuan, a year-on-year decrease of 15.23%, with a gross margin of 49.71%, down by 0.02 percentage points [1] - The company is focusing on cultivating key products and exploring potential products to ensure stable development in its pharmaceutical manufacturing business [1] Product Sales - In the first half of 2025, sales revenue for products such as Baoji series, anti-inflammatory analgesic plaster, methoxyflavone, Kunxian capsule, summer chrysanthemum series, candesartan cilexetil tablets, and Xiaoke pill experienced relatively rapid growth year-on-year [1] Market Challenges - The company faces pressure on performance due to intensified industry competition and insufficient demand [1] - The rating has been adjusted to "overweight" [1]